MedTrace Logo

To Assess the Effect of Dexamethasone Eye Drops on the Retinopathy of Prematurity Outcome

NCT06775353 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2017

Last updated 2025-01-22

No results posted yet for this study

Summary

The purpose is to compare the treatment frequency of preterm infants who developed severe Retinopathy of Prematurity (ROP) during the years 2015-2018 with 2020-2021 in the country, using the statistical method 'difference in differences' to investigate the potential for scientific evidence regarding the introduction of dexamethasone eye drops' effect on the development of severe treatment-requiring ROP. During these years, the investigatots assess that the recommended oxygen saturation levels for preterm infants have remained stable at each clinic, which will serve as its own reference.

Conditions

  • Retinopathy of Prematurity (ROP)

Interventions

DRUG

Dexamethasone eyedrop

Infants who developed stages of pretreatment-requiring severe ROP were usually given one eyedrop of dexamethasone daily until the ROP changes regressed.

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Eligibility

Min Age
31 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-12-31
Completion
2025-01-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06775353 on ClinicalTrials.gov